Insulet (PODD)
(Delayed Data from NSDQ)
$204.42 USD
+11.84 (6.15%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $202.65 -1.77 (-0.87%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Insulet Corporation [PODD]
Reports for Purchase
Showing records 221 - 240 ( 345 total )
Company: Insulet Corporation
Industry: Medical - Products
2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Amgen Highlights Solid Launch of Neulasta On- Body Injector (OmniPod inside)
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
June Estimate Suggests On-Body Injector Represents 10% of Neulasta Sales; Positive for PODD''s Drug Delivery Business Outlook
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
June Estimate Suggests On-Body Injector Represents 10% of Neulasta Sales; Positive for PODD''s Drug Delivery Business Outlook
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices - 2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15 Remains Positive
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices - Takeaways from J-J''s 2Q15 Results
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Positive OmniPod Reimbursement Developments; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
FDA Warning Letter Highlights Past Quality Issues; No Impact Expected to the Business
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
FDA Warning Letter Highlights Past Quality Issues; No Impact Expected to the Business
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q1 misses on top and bottom line, lowering to SELL; PT to $22.75
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Stability in US OmniPod More Than Offset by Shortfalls Elsewhere; Lowering PT to $36; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of ~5,400 pump users (2007 - present)
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Amgen Partnership Off to a Strong Start
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
1Q15 Preview: Trends Look Better Than Initially Expected
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Proprietary Survey of Diabetes Educators Positive for Insulet and Tandem; Raising PT of PODD to $38
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulet Strengthens Bench by Hiring Experienced CFO; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulet Strengthens Bench by Hiring Experienced CFO; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q4 inline with preannouncement, management sets new tone; PT to $27.50
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Despite the Near-Term Challenges, Long-Term Thesis Remains Unchanged; Lowering PT to $34; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.